( December 9, 2025, 3:08 PM EST) -- WASHINGTON, D.C. — In an amicus curiae brief, the U.S. government tells the U.S. Supreme Court that it should take up a bioequivalent drug manufacturer’s petition for a writ of certiorari because the Federal Circuit U.S. Court of Appeals’ finding that the petitioner’s “skinny label” generic version of a prescription cardiovascular medication constituted reverse infringement is at odds with the intention behind carve-outs under the Hatch-Waxman Act....